Yes, FGFs and FGFRs represent promising therapeutic targets in cancer. Several strategies are being explored, including:
- FGFR Inhibitors: Small molecule inhibitors targeting FGFRs have shown efficacy in preclinical and clinical studies. Examples include erdafitinib and pemigatinib. - Monoclonal Antibodies: These antibodies specifically bind to FGFs or FGFRs, blocking their interaction and downstream signaling. - Ligand Traps: Soluble FGFRs act as decoys, sequestering FGFs and preventing them from binding to cell surface receptors.
